Oct 29, 2025
Immutep Quarterly Activities Report Q1 FY26
Oct 20, 2025
Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025
Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer
Oct 13, 2025
Immutep Announces Successful Completion of FDA Project Optimus Requirements
Oct 09, 2025
Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
